Loading…

The Utility of Vitamin K3 (Menadione) against Pancreatic Cancer

Background: To evaluate the efficacy of vitamin K3 (VK3) against pancreatic cancer, the molecular mechanism of VK3 or gemcitabine (GEM)-induced inhibition of proliferation was characterized. Materials and Methods: The cell viability was determined using the 3-[4,5-dimethylthiazol]-2,5-diphenyl tetra...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2008-01, Vol.28 (1A), p.45-50
Main Authors: OSADA, Shinji, TOMITA, Hiroyuki, TANAKA, Yoshihiro, TOKUYAMA, Yasuharu, TANAKA, Hidenori, SAKASHITA, Fumio, TAKAHASHI, Takao
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 50
container_issue 1A
container_start_page 45
container_title Anticancer research
container_volume 28
creator OSADA, Shinji
TOMITA, Hiroyuki
TANAKA, Yoshihiro
TOKUYAMA, Yasuharu
TANAKA, Hidenori
SAKASHITA, Fumio
TAKAHASHI, Takao
description Background: To evaluate the efficacy of vitamin K3 (VK3) against pancreatic cancer, the molecular mechanism of VK3 or gemcitabine (GEM)-induced inhibition of proliferation was characterized. Materials and Methods: The cell viability was determined using the 3-[4,5-dimethylthiazol]-2,5-diphenyl tetrazolium bromide (MTT) test method. The expressions of cellular proteins were evaluated by Western blot analysis. For morphological studies of the in vivo transplanted cancer cells, the tissues were stained with hematoxylin and eosin. Results: The IC 50 of VK3 for pancreatic cancer cells was calculated for 42.1±3.5 μM. Western blot analysis showed that VK3 induced rapid phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH 2 -terminal kinase (JNK) 30 minutes after application. ERK but not JNK phosphorylation was maintained for at least 12 hours. Activation of apoptosis by VK3, as shown by molecular weight shifts of the pro-activated 32-kDa form of caspase-3 and poly(ADP-ribose)polymerase (PARP) cleavage of the 112-kDa form, was found. Treatment with the thiol antioxidant, L-cysteine (>0.2 mM), completely abrogated the VK3-induced phosphorylation of ERK, but not the JNK, and inhibition of proliferation. A caspase-3 inhibitor antagonized caspase-3 activation, but had no inhibitory effect on the proliferative activity of VK3. GEM at concentrations >0.1 μg/ml was found to inhibit cell proliferation after 24 hours. GEM also induced phosphorylation of JNK, activation of caspase-3 and accumulation of cyclin B1. Local application of VK3 was found to induce extensive tumor tissue necrosis, but slight hematemesis without necrosis was observed 48 hours after GEM injection. In Western blot, ERK, but not JNK phosphorylation, was clearly detected in response to VK3 injection into the tumor tissue. Conclusion: The action of VK3 may lead to a favorable outcome against pancreatic cancer, and the detection of ERK phosphorylation in the tissue is important for predicting this effect.
format article
fullrecord <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_18383823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18383823</sourcerecordid><originalsourceid>FETCH-LOGICAL-h268t-67b97d44c2cf6eb3fd9deb6fe8856f47bb301f0a711f13c387e056766ed8e7af3</originalsourceid><addsrcrecordid>eNo9z01Lw0AQBuBFFBurf0H2oKCHwG42-5GTlOIXVvTQeg2zyWyzkqRlNyL990ZaZQ7vHB5eZo5IwnXBUy0FOyYJyyRLNWNyQs5i_GRMqcKIUzLhRoyTiYTcLRukq8G3ftjRjaMffoDO9_RF0JtX7KH2mx5vKazB93Gg79BXAWHwFZ2PK4ZzcuKgjXhxyClZPdwv50_p4u3xeT5bpE2mzJAqbQtd53mVVU6hFa4uarTKoTFSuVxbKxh3DDTnjotKGI1MKq0U1gY1ODEll_ve7ZftsC63wXcQduXfJyO4PgCIFbQujOf5-O8yxpXUxa-72rvGr5tvH7CMHbTtWCtKCJkp-azMpfgBUXpeLA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Utility of Vitamin K3 (Menadione) against Pancreatic Cancer</title><source>EZB Electronic Journals Library</source><creator>OSADA, Shinji ; TOMITA, Hiroyuki ; TANAKA, Yoshihiro ; TOKUYAMA, Yasuharu ; TANAKA, Hidenori ; SAKASHITA, Fumio ; TAKAHASHI, Takao</creator><creatorcontrib>OSADA, Shinji ; TOMITA, Hiroyuki ; TANAKA, Yoshihiro ; TOKUYAMA, Yasuharu ; TANAKA, Hidenori ; SAKASHITA, Fumio ; TAKAHASHI, Takao</creatorcontrib><description>Background: To evaluate the efficacy of vitamin K3 (VK3) against pancreatic cancer, the molecular mechanism of VK3 or gemcitabine (GEM)-induced inhibition of proliferation was characterized. Materials and Methods: The cell viability was determined using the 3-[4,5-dimethylthiazol]-2,5-diphenyl tetrazolium bromide (MTT) test method. The expressions of cellular proteins were evaluated by Western blot analysis. For morphological studies of the in vivo transplanted cancer cells, the tissues were stained with hematoxylin and eosin. Results: The IC 50 of VK3 for pancreatic cancer cells was calculated for 42.1±3.5 μM. Western blot analysis showed that VK3 induced rapid phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH 2 -terminal kinase (JNK) 30 minutes after application. ERK but not JNK phosphorylation was maintained for at least 12 hours. Activation of apoptosis by VK3, as shown by molecular weight shifts of the pro-activated 32-kDa form of caspase-3 and poly(ADP-ribose)polymerase (PARP) cleavage of the 112-kDa form, was found. Treatment with the thiol antioxidant, L-cysteine (&gt;0.2 mM), completely abrogated the VK3-induced phosphorylation of ERK, but not the JNK, and inhibition of proliferation. A caspase-3 inhibitor antagonized caspase-3 activation, but had no inhibitory effect on the proliferative activity of VK3. GEM at concentrations &gt;0.1 μg/ml was found to inhibit cell proliferation after 24 hours. GEM also induced phosphorylation of JNK, activation of caspase-3 and accumulation of cyclin B1. Local application of VK3 was found to induce extensive tumor tissue necrosis, but slight hematemesis without necrosis was observed 48 hours after GEM injection. In Western blot, ERK, but not JNK phosphorylation, was clearly detected in response to VK3 injection into the tumor tissue. Conclusion: The action of VK3 may lead to a favorable outcome against pancreatic cancer, and the detection of ERK phosphorylation in the tissue is important for predicting this effect.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 18383823</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Animals ; Antimetabolites, Antineoplastic - pharmacology ; Biological and medical sciences ; Cell Growth Processes - drug effects ; Cell Line, Tumor ; Deoxycytidine - analogs &amp; derivatives ; Deoxycytidine - pharmacology ; Gastroenterology. Liver. Pancreas. Abdomen ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - pathology ; Rats ; Rats, Wistar ; Tumors ; Vitamin K 3 - pharmacology ; Vitamins - pharmacology</subject><ispartof>Anticancer research, 2008-01, Vol.28 (1A), p.45-50</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4023</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20165793$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18383823$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OSADA, Shinji</creatorcontrib><creatorcontrib>TOMITA, Hiroyuki</creatorcontrib><creatorcontrib>TANAKA, Yoshihiro</creatorcontrib><creatorcontrib>TOKUYAMA, Yasuharu</creatorcontrib><creatorcontrib>TANAKA, Hidenori</creatorcontrib><creatorcontrib>SAKASHITA, Fumio</creatorcontrib><creatorcontrib>TAKAHASHI, Takao</creatorcontrib><title>The Utility of Vitamin K3 (Menadione) against Pancreatic Cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: To evaluate the efficacy of vitamin K3 (VK3) against pancreatic cancer, the molecular mechanism of VK3 or gemcitabine (GEM)-induced inhibition of proliferation was characterized. Materials and Methods: The cell viability was determined using the 3-[4,5-dimethylthiazol]-2,5-diphenyl tetrazolium bromide (MTT) test method. The expressions of cellular proteins were evaluated by Western blot analysis. For morphological studies of the in vivo transplanted cancer cells, the tissues were stained with hematoxylin and eosin. Results: The IC 50 of VK3 for pancreatic cancer cells was calculated for 42.1±3.5 μM. Western blot analysis showed that VK3 induced rapid phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH 2 -terminal kinase (JNK) 30 minutes after application. ERK but not JNK phosphorylation was maintained for at least 12 hours. Activation of apoptosis by VK3, as shown by molecular weight shifts of the pro-activated 32-kDa form of caspase-3 and poly(ADP-ribose)polymerase (PARP) cleavage of the 112-kDa form, was found. Treatment with the thiol antioxidant, L-cysteine (&gt;0.2 mM), completely abrogated the VK3-induced phosphorylation of ERK, but not the JNK, and inhibition of proliferation. A caspase-3 inhibitor antagonized caspase-3 activation, but had no inhibitory effect on the proliferative activity of VK3. GEM at concentrations &gt;0.1 μg/ml was found to inhibit cell proliferation after 24 hours. GEM also induced phosphorylation of JNK, activation of caspase-3 and accumulation of cyclin B1. Local application of VK3 was found to induce extensive tumor tissue necrosis, but slight hematemesis without necrosis was observed 48 hours after GEM injection. In Western blot, ERK, but not JNK phosphorylation, was clearly detected in response to VK3 injection into the tumor tissue. Conclusion: The action of VK3 may lead to a favorable outcome against pancreatic cancer, and the detection of ERK phosphorylation in the tissue is important for predicting this effect.</description><subject>Animals</subject><subject>Antimetabolites, Antineoplastic - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Growth Processes - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Deoxycytidine - analogs &amp; derivatives</subject><subject>Deoxycytidine - pharmacology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Tumors</subject><subject>Vitamin K 3 - pharmacology</subject><subject>Vitamins - pharmacology</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNo9z01Lw0AQBuBFFBurf0H2oKCHwG42-5GTlOIXVvTQeg2zyWyzkqRlNyL990ZaZQ7vHB5eZo5IwnXBUy0FOyYJyyRLNWNyQs5i_GRMqcKIUzLhRoyTiYTcLRukq8G3ftjRjaMffoDO9_RF0JtX7KH2mx5vKazB93Gg79BXAWHwFZ2PK4ZzcuKgjXhxyClZPdwv50_p4u3xeT5bpE2mzJAqbQtd53mVVU6hFa4uarTKoTFSuVxbKxh3DDTnjotKGI1MKq0U1gY1ODEll_ve7ZftsC63wXcQduXfJyO4PgCIFbQujOf5-O8yxpXUxa-72rvGr5tvH7CMHbTtWCtKCJkp-azMpfgBUXpeLA</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>OSADA, Shinji</creator><creator>TOMITA, Hiroyuki</creator><creator>TANAKA, Yoshihiro</creator><creator>TOKUYAMA, Yasuharu</creator><creator>TANAKA, Hidenori</creator><creator>SAKASHITA, Fumio</creator><creator>TAKAHASHI, Takao</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20080101</creationdate><title>The Utility of Vitamin K3 (Menadione) against Pancreatic Cancer</title><author>OSADA, Shinji ; TOMITA, Hiroyuki ; TANAKA, Yoshihiro ; TOKUYAMA, Yasuharu ; TANAKA, Hidenori ; SAKASHITA, Fumio ; TAKAHASHI, Takao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h268t-67b97d44c2cf6eb3fd9deb6fe8856f47bb301f0a711f13c387e056766ed8e7af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Antimetabolites, Antineoplastic - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Growth Processes - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Deoxycytidine - analogs &amp; derivatives</topic><topic>Deoxycytidine - pharmacology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Tumors</topic><topic>Vitamin K 3 - pharmacology</topic><topic>Vitamins - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OSADA, Shinji</creatorcontrib><creatorcontrib>TOMITA, Hiroyuki</creatorcontrib><creatorcontrib>TANAKA, Yoshihiro</creatorcontrib><creatorcontrib>TOKUYAMA, Yasuharu</creatorcontrib><creatorcontrib>TANAKA, Hidenori</creatorcontrib><creatorcontrib>SAKASHITA, Fumio</creatorcontrib><creatorcontrib>TAKAHASHI, Takao</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OSADA, Shinji</au><au>TOMITA, Hiroyuki</au><au>TANAKA, Yoshihiro</au><au>TOKUYAMA, Yasuharu</au><au>TANAKA, Hidenori</au><au>SAKASHITA, Fumio</au><au>TAKAHASHI, Takao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Utility of Vitamin K3 (Menadione) against Pancreatic Cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>28</volume><issue>1A</issue><spage>45</spage><epage>50</epage><pages>45-50</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: To evaluate the efficacy of vitamin K3 (VK3) against pancreatic cancer, the molecular mechanism of VK3 or gemcitabine (GEM)-induced inhibition of proliferation was characterized. Materials and Methods: The cell viability was determined using the 3-[4,5-dimethylthiazol]-2,5-diphenyl tetrazolium bromide (MTT) test method. The expressions of cellular proteins were evaluated by Western blot analysis. For morphological studies of the in vivo transplanted cancer cells, the tissues were stained with hematoxylin and eosin. Results: The IC 50 of VK3 for pancreatic cancer cells was calculated for 42.1±3.5 μM. Western blot analysis showed that VK3 induced rapid phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH 2 -terminal kinase (JNK) 30 minutes after application. ERK but not JNK phosphorylation was maintained for at least 12 hours. Activation of apoptosis by VK3, as shown by molecular weight shifts of the pro-activated 32-kDa form of caspase-3 and poly(ADP-ribose)polymerase (PARP) cleavage of the 112-kDa form, was found. Treatment with the thiol antioxidant, L-cysteine (&gt;0.2 mM), completely abrogated the VK3-induced phosphorylation of ERK, but not the JNK, and inhibition of proliferation. A caspase-3 inhibitor antagonized caspase-3 activation, but had no inhibitory effect on the proliferative activity of VK3. GEM at concentrations &gt;0.1 μg/ml was found to inhibit cell proliferation after 24 hours. GEM also induced phosphorylation of JNK, activation of caspase-3 and accumulation of cyclin B1. Local application of VK3 was found to induce extensive tumor tissue necrosis, but slight hematemesis without necrosis was observed 48 hours after GEM injection. In Western blot, ERK, but not JNK phosphorylation, was clearly detected in response to VK3 injection into the tumor tissue. Conclusion: The action of VK3 may lead to a favorable outcome against pancreatic cancer, and the detection of ERK phosphorylation in the tissue is important for predicting this effect.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>18383823</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0250-7005
ispartof Anticancer research, 2008-01, Vol.28 (1A), p.45-50
issn 0250-7005
1791-7530
language eng
recordid cdi_pubmed_primary_18383823
source EZB Electronic Journals Library
subjects Animals
Antimetabolites, Antineoplastic - pharmacology
Biological and medical sciences
Cell Growth Processes - drug effects
Cell Line, Tumor
Deoxycytidine - analogs & derivatives
Deoxycytidine - pharmacology
Gastroenterology. Liver. Pancreas. Abdomen
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - pathology
Rats
Rats, Wistar
Tumors
Vitamin K 3 - pharmacology
Vitamins - pharmacology
title The Utility of Vitamin K3 (Menadione) against Pancreatic Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A06%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Utility%20of%20Vitamin%20K3%20(Menadione)%20against%20Pancreatic%20Cancer&rft.jtitle=Anticancer%20research&rft.au=OSADA,%20Shinji&rft.date=2008-01-01&rft.volume=28&rft.issue=1A&rft.spage=45&rft.epage=50&rft.pages=45-50&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E18383823%3C/pubmed_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h268t-67b97d44c2cf6eb3fd9deb6fe8856f47bb301f0a711f13c387e056766ed8e7af3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/18383823&rfr_iscdi=true